Q1 2024 Revenue of $22.9 million Q1 2024 Net loss of $5.9 million Q1 2024 Adjusted EBITDA loss of $0.0 million All figures are reported in United [...]
Presentations highlight data supporting FILSPARI®(sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients […]
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company […]